Skip to main content

COVID-19 Topic Center

Oncology Expert Insights

Population Health Learning Network
This article explains how David Silver, MD, chief of urology and director of the Prostate Center at Maimonides Medical Center, changed his treatment decisions amid the pandemic, and highlights the use of the new CPT code for high intensity focused ultrasound that now allows hospitals to bill…
Population Health Learning Network
Anthony Mato, MD, Memorial Sloan Kettering Cancer Center, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with chronic lymphocytic leukemia (CLL) in the clinical practice setting, using the informCLL prospective registry.  
Population Health Learning Network
Constantine Tam, MD, director of Hematology, St Vincent Hospital, discusses the phase 3 SYMPATICO study that examined the use ibrutinib plus venetoclax for the treatment of mantle cell lymphoma.   
Population Health Learning Network
Based on a median follow-up of four years, John Allen, MD, assistant professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine, New York-Presbyterian Hospital, explains how first-line ibrutinib-based treatment resulted in sustained efficacy with high…
Population Health Learning Network
William G. Wierda, MD, PhD, professor, Department of Leukemia, University of Texas MD Anderson Cancer Center, discusses the results of the Phase II CAPTIVATE study, and highlights how the use of Ibrutinib plus Venetoclax confers high rates of peripheral blood and bone marrow undetectable…
Population Health Learning Network
Alfred L Garfall, MD, MS, assistant professor of Medicine, Perelman School of Medicine, University of Pennsylvania, discusses his recent study presented at ASH 2020, which examined the use of teclistamab for the treatment of multiple myeloma, highlighting a manageable safety profile, including…
Population Health Learning Network
Deepu Madduri, MD, assistant professor, Hematology and Medical Oncology of the Mount Sinai Hospital, Mount Sinai Beth Israel, discusses the results of the CARTITUDE-1 study, which analyzed ciltacabtagene autoleucel, a CAR-T-cell therapy with 2 B-cell maturation antigen–targeting single-domain…
Population Health Learning Network
Raymond Comenzo, MD, hematologist, reviews the findings of the phase III ANDROMEDA trial and details how the addition of daratumumab improves hematologic responses and clinical outcomes.    Reference: Kastritis E, Palladini G, Minnema MC, et al. Subcutaneous daratumumab +…
Back to Top